Vifor Pharma Group Reports Continued Growth in H1 2020

Regulatory News: Vifor Pharma Group reported growth in H1 2020, despite challenges to patient access conditions caused by the COVID-19 pandemic. The financial guidance has been updated to reflect C

8월 6일 15:02

VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)

Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (NASDAQ: CCXI) today announced topline data from a forty-six (46) patient phase-II dose-ranging trial in

5월 18일 17:36

92nd Vifor Pharma Group Annual General Meeting

Regulatory News: At the 92nd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the current situation a

5월 15일 16:31

Vifor Pharma Announces Akebia’s Positive Top-Line Results From Global Phase-III Program of vadadustat for Treatment of Anaemia Due to Chronic Kidney Disease in Adult Dialysis-Dependent Patients

Regulatory News: Vifor Pharma announced that its partner, Akebia Therapeutics, Inc., today reported positive top-line results from INNO2VATE, Akebia’s global phase-III cardiovascular outcomes progr

5월 6일 10:36

Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance

Regulatory News: Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The c

3월 12일 15:35

Pioneering Project for Pharmaceutics - Vifor Pharma and the University of Basel are Jointly Establishing the World’s First Research Professorship for Nanopharmaceutical and Regulatory Science

Nanopharmaceutics promises ground-breaking innovation in the development of medicines: · The Vifor Pharma Group is endowing two professorships for Nanopharmaceutical and Regulatory Science at the U

2019년 5월 27일 10:53